FDA picks Wave's DMD program for innovative trial pilot

Wave Life Sciences Ltd. (NASDAQ:WVE) said FDA has selected a Phase II/III trial of its Duchenne muscular dystrophy candidate suvodirsen

Read the full 204 word article

User Sign In